Feed Preview

LRRK2 & Immunity During Infection (MDS)

LRRK2 & Immunity During Infection (MDS) diagram by Designua, Shutterstock & Pleiotrope, Wikimedia
Designua, Shutterstock & Pleiotrope, Wikimedia

Mutations in the LRRK2 gene are a risk-factor for developing Parkinson’s disease. However, LRRK2 has been shown to function as a central regulator of vesicular trafficking, infection, immunity, and inflammation. Here is the latest research on the role of this kinase on immunity during infection.

Top 20 most recent papers

LRRK2 kinase in Parkinson's disease

ScienceApril 7, 2018
Dario R Alessi, Esther Sammler
NPJ Parkinson's Disease

LRRK2 levels in immune cells are increased in Parkinson's disease

NPJ Parkinson's DiseaseJune 27, 2017
D A CookMalú G Tansey
Brain : a Journal of Neurology

Mutant LRRK2 mediates peripheral and central immune responses leading to neurodegeneration in vivo

Brain : a Journal of NeurologyMay 26, 2018
Elena KozinaRichard J Smeyne
Science Translational Medicine

An increase in LRRK2 suppresses autophagy and enhances Dectin-1-induced immunity in a mouse model of colitis

Science Translational MedicineJune 8, 2018
Tetsuya TakagawaWarren Strober
NPJ Parkinson's Disease

Parkinson's progression prediction using machine learning and serum cytokines

NPJ Parkinson's DiseaseAugust 3, 2019
Diba Ahmadi RastegarNicolas Dzamko
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology

Crohn's and Parkinson's Disease-Associated LRRK2 Mutations Alter Type II Interferon Responses in Human CD14+ Blood Monocytes Ex Vivo

Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune PharmacologyMarch 18, 2020
Tsuneya IkezuZbigniew K Wszolek
Frontiers in Neuroscience

Leucine Rich Repeat Kinase 2 and Innate Immunity

Frontiers in NeuroscienceMarch 27, 2020
Diba Ahmadi Rastegar, Nicolas Dzamko
Revue neurologique

The genetic landscape of Parkinson's disease

Revue neurologiqueSeptember 25, 2018
A LunatiA Brice
Advances in Neurobiology

LRRK2 and the Immune System

Advances in NeurobiologyMarch 30, 2017
Nicolas Dzamko
Biochemical and Biophysical Research Communications

Phosphorylation of p53 by LRRK2 induces microglial tumor necrosis factor α-mediated neurotoxicity

Biochemical and Biophysical Research CommunicationsDecember 5, 2016
Dong Hwan HoIl-Hong Son
Movement Disorders : Official Journal of the Movement Disorder Society

LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients

Movement Disorders : Official Journal of the Movement Disorder SocietyJanuary 1, 2019
Farzaneh AtashrazmNicolas Dzamko
Movement Disorders : Official Journal of the Movement Disorder Society

Lysosome and Inflammatory Defects in GBA1-Mutant Astrocytes Are Normalized by LRRK2 Inhibition

Movement Disorders : Official Journal of the Movement Disorder SocietyFebruary 9, 2020
Anwesha SanyalMatthew J LaVoie

See more papers from this feed

Related Feeds

Allen Institute for Brain Science Network (MDS)

The Allen Institute for Brain Science Network is a not-for-profit biomedical research organization that provides open access to multiple neuroscience tools and resources. Find the latest research from tjr Allen Institute for Brain Science Network here.

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.

Alpha-Synuclein Antibody Therapeutics (MDS)

Alpha-synuclein is an integral component of Lewy bodies which are comprised of protein clumps and are a pathological hallmark of Parkinson’s disease. They have also been detected in several other neurodegenerative diseases, known as synucleopathies. Here is the latest research on alpha-synuclein antibody therapeutics.

Astrocytes & Huntington’s Disease (MDS)

Astrocytes are abundant within the central nervous system and their dysfunction has been thought to be an important contributor to some neurodegenerative diseases, in particular Huntington’s disease. Damage to these cells may make neurons more susceptible to degeneration. Here is the latest research on astrocytes and Huntington’s disease.

Ataxia telangiectasia (MDS)

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.

Ataxias (MDS)

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Atypical Parkinsonism (MDS)

Atypical Parkinsonism presents with the same signs and symptoms of Parkinson's disease, but do not respond to typical Parkionson's disease treatment with levodopa. Atypical Parkinsonism is thought to be associated with abnormal protein buildup within brain cells. Here is the latest on Atypical Parkinsonism.

Autophagy: Cancer & Parkinson (MDS)

Autophagy leads to degradation of damaged proteins and organelles by the lysosome. Impaired autophagy has been implicated in several diseases. Here is the role of autophagy in cancer and Parkinson’s.

BRAIN Initiative Cell Census Network (MDS)

The BRAIN Initiative Cell Census Network aims to identify and provide experimental access to the different brain cell types to determine their roles in health and disease. Discover the latest research from researchers in the BRAIN Initiative Cell Census Network here.

Basal ganglia in Parkinson's disease (MDS)

The basal ganglia is comprised of the neostriatum, the external and internal pallidal segments, the subthalamic nucleus, the substantia nigra pars reticulata, and the pars compacta of the substantia nigra. The basal ganglia circuitry is responsible for the correct execution of voluntary movements and is implicated in Parkinson's disease. Here is the latest research investigating the basal ganglia in Parkinson's disease.

© 2020 Meta ULC. All rights reserved